Three months ago, in its third-quarter report, Madrigal pointed out that it achieved a key goal early by gaining 80% coverage ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

B. Riley upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Thursday morning, Marketbeat ...

BofA raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $239 from $154 and keeps an Underperform rating on ...

Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

Madrigal Pharmaceuticals' Rezdiffra had a strong launch with $103.3M in Q4 sales and solid liquidity. See why I have a ...

B. Riley upgraded Madrigal Pharmaceuticals (MDGL) to Buy from Neutral with a price target of $422, up from $236. The firm notes the erosion of ...

Oppenheimer raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $475 from $400 and keeps an Outperform rating on the shares ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported two-year results from the open-label compensated MASH cirrhosis (F4c) ...